These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 37461454)
1. Efficacy of Plasma Rich in Growth Factors (PRGF) in Stage 1 Neurotrophic Keratitis. Ghalibafan S; Osei K; Amescua G; Sabater A Res Sq; 2023 Jun; ():. PubMed ID: 37461454 [TBL] [Abstract][Full Text] [Related]
2. Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops. Sanchez-Avila RM; Merayo-Lloves J; Riestra AC; Fernandez-Vega Cueto L; Anitua E; Begoña L; Muruzabal F; Orive G Int Ophthalmol; 2018 Jun; 38(3):1193-1204. PubMed ID: 28620707 [TBL] [Abstract][Full Text] [Related]
3. A multicenter report of the use of plasma rich in growth factors (PRGF) for the treatment of patients with ocular surface diseases in North America. Soifer M; Tovar A; Wang M; Mousa HM; Yennam S; Sabater AL; Pflugfelder SC; Perez VL Ocul Surf; 2022 Jul; 25():40-48. PubMed ID: 35489588 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Use of Highly Concentrated Autologous Platelet-Rich Plasma and Platelet-Rich Fibrin Membrane to Improve the Outcome in the Management of Severe Dry Eye Disease, Corneal Neurotrophic Ulcer and Corneal Burn. Hassan A; Telandro A; Barguigua A; Baba M; Körber N Cureus; 2024 Jan; 16(1):e51794. PubMed ID: 38322082 [TBL] [Abstract][Full Text] [Related]
5. Corneal changes in neurosurgically induced neurotrophic keratitis. Lambiase A; Sacchetti M; Mastropasqua A; Bonini S JAMA Ophthalmol; 2013 Dec; 131(12):1547-53. PubMed ID: 24158681 [TBL] [Abstract][Full Text] [Related]
6. Plasma rich in growth factors eye drops to treat secondary ocular surface disorders in patients with glaucoma. Sánchez-Avila RM; Merayo-Lloves J; Fernández ML; Rodríguez-Gutiérrez LA; Rodríguez-Calvo PP; Fernández-Vega Cueto A; Muruzabal F; Orive G; Anitua E Int Med Case Rep J; 2018; 11():97-103. PubMed ID: 29760570 [TBL] [Abstract][Full Text] [Related]
7. Ocular pain in ocular graft-versus-host disease patients with neurotrophic keratopathy. Wang S; Singh RB; Yuksel E; Musayeva A; Sinha S; Taketani Y; Dohlman TH; Dana R Ocul Surf; 2022 Oct; 26():142-147. PubMed ID: 35948166 [TBL] [Abstract][Full Text] [Related]
8. Neurotrophic keratopathy: An updated understanding. Neurotrophic Keratopathy Study Group Ocul Surf; 2023 Oct; 30():129-138. PubMed ID: 37666470 [TBL] [Abstract][Full Text] [Related]
9. [A clinical analysis of 46 cases of neurotrophic keratitis]. Tian L; Sun XG Zhonghua Yan Ke Za Zhi; 2020 Apr; 56(4):294-298. PubMed ID: 32306622 [No Abstract] [Full Text] [Related]
10. Neurotrophic keratopathy: current challenges and future prospects. NaPier E; Camacho M; McDevitt TF; Sweeney AR Ann Med; 2022 Dec; 54(1):666-673. PubMed ID: 35243932 [TBL] [Abstract][Full Text] [Related]
11. Long-term clinical efficacy of topical treatment with recombinant human nerve growth factor in neurotrophic keratopathy: a novel cure for a rare degenerative corneal disease? Bruscolini A; Marenco M; Albanese GM; Lambiase A; Sacchetti M Orphanet J Rare Dis; 2022 Feb; 17(1):57. PubMed ID: 35172847 [TBL] [Abstract][Full Text] [Related]
12. Plasma rich in growth factors (PRGF) eye drops stimulates scarless regeneration compared to autologous serum in the ocular surface stromal fibroblasts. Anitua E; de la Fuente M; Muruzabal F; Riestra A; Merayo-Lloves J; Orive G Exp Eye Res; 2015 Jun; 135():118-26. PubMed ID: 25708868 [TBL] [Abstract][Full Text] [Related]
13. Prevalence of neurotrophic keratopathy in patients with chronic ocular graft-versus-host disease. Singh RB; Yuksel E; Sinha S; Wang S; Taketani Y; Luznik Z; Yin J; Dohlman TH; Dana R Ocul Surf; 2022 Oct; 26():13-18. PubMed ID: 35843560 [TBL] [Abstract][Full Text] [Related]
15. Use of Plasma Rich in Growth Factors and ReGeneraTing Agent Matrix for the Treatment of Corneal Diseases. Sánchez-Ávila RM; Uribe-Badillo E; Fernández-Vega González C; Muruzabal F; de la Sen-Corcuera B; Baamonde B; Quirós LM; Anitua E; Merayo-Lloves J Vision (Basel); 2021 Jul; 5(3):. PubMed ID: 34287367 [TBL] [Abstract][Full Text] [Related]
16. Autologous serum application in the treatment of neurotrophic keratopathy. Matsumoto Y; Dogru M; Goto E; Ohashi Y; Kojima T; Ishida R; Tsubota K Ophthalmology; 2004 Jun; 111(6):1115-20. PubMed ID: 15177961 [TBL] [Abstract][Full Text] [Related]
17. Effect of recombinant human nerve growth factor treatment on corneal nerve regeneration in patients with neurotrophic keratopathy. Balbuena-Pareja A; Bogen CS; Cox SM; Hamrah P Front Neurosci; 2023; 17():1210179. PubMed ID: 37965220 [TBL] [Abstract][Full Text] [Related]
18. Characteristics of the ocular surface in neurotrophic keratitis induced by trigeminal nerve injury following neurosurgery. Xie C; Liu B; Zhao X; He Q; Liu L; Wei R Int Ophthalmol; 2023 Apr; 43(4):1229-1240. PubMed ID: 36115903 [TBL] [Abstract][Full Text] [Related]
19. Aqueous tear production in patients with neurotrophic keratitis. Heigle TJ; Pflugfelder SC Cornea; 1996 Mar; 15(2):135-8. PubMed ID: 8925660 [TBL] [Abstract][Full Text] [Related]
20. Effects of heat-treatment on plasma rich in growth factors-derived autologous eye drop. Anitua E; Muruzabal F; De la Fuente M; Merayo-Lloves J; Orive G Exp Eye Res; 2014 Feb; 119():27-34. PubMed ID: 24345372 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]